Refractory mucocutaneous infections by herpes simplex virus (HSV) in hematopoietic cell transplant recipients: A real-world, multicenter study

Clicks: 3
ID: 318046
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #202 of 214 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background We examined treatment patterns and clinical outcomes of adult hematopoietic cell transplant (HCT) recipients with refractory mucocutaneous herpes simplex virus (HSV) infection from 7 US centers. Methods Multicenter, retrospective study of laboratory confirmed HSV infection and failure to improve after ≥7 days of appropriately dosed anti-HSV therapies. Resistance testing was performed at clinicians’ discretion. Therapies were captured for the first refractory HSV infection post-HCT (index episode). Time to complete lesion healing, toxicities, and HSV recurrence up to 1 year from index HSV episode lesion healing were extracted from EMR. The cumulative incidence function was used to estimate time to healing with death as competing risk. Results Of 125 patients, acyclovir resistance was confirmed in 85/104 patients (81.7%) tested. First therapy was nucleoside analogue in 100 patients and foscarnet in 25. One hundred and ten patients (88%) received second line therapy(ies), including foscarnet (94), intravenous cidofovir (6), and/or topical antivirals (21). Mean treatment durations (standard deviation) were 21.8 days (13.8), 20.3 (10.1), and 41.0 (37.5) for foscarnet, cidofovir, and topicals, respectively. Complete healing occurred in 69 patients (55.2%) at a median of 38 days (range 257) from the anti-HSV therapy start. Nephrotoxicity was reported during 40.4% of foscarnet and 50.0% of cidofovir courses, respectively. Among 69 patients with completed healing, 27 (39.1%) experienced HSV recurrence during follow up. Conclusion Our study highlights the challenges of managing refractory HSV post-HCT during the study timeframe, and underscores the unmet need for safer, more effective and orally bioavailable therapies for refractory HSV.
Reference Key
openalex_W7165383975 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Genovefa A. Papanicolaou, Y S Lee, Tali Shafat, Y. Li, Jo‐Anne H. Young, Amy Spallone, Karam M. Obeid, Gunjan L. Shah, Patrick W Flaherty, Mandeep K Sekhon, Kitty Chiu, Veronica Dioverti, Sarah P. Hammond, Sanjeet Dadwal, Joshua A. Hill, Camille N. Kotton, Veronica Miller, Per Ljungman, Roy F Chemaly
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag377
URL
https://doi.org/10.1093/ofid/ofag377
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.